Introduction
Mobilized peripheral blood stem cells (PBSCs) have become the main source for autologous or allogeneic transplantation after myeloablative therapy in patients with hematolymphoid malignancies or solid tumors. Classical strategies for PBSC mobilization include administration of granulocyte colony-stimulating factor (G-CSF) alone or in combination with other cytokines or myelosuppressive chemotherapy. 1 PBSC mobilization and collection have been optimized in numerous clinical trials, 2 but a significant proportion of patients fail mobilization. 3 In recent years, some of the underlying physiology of PBSCs has been elucidated, leading to the development of new mobilization strategies. Expression of the G-CSF receptor on stem cells is not required for mobilization. G-CSF or myelosuppressive therapy acts through secondary pathways, including the chemokine stromal-derived factor-1 and its receptor CXCR4. New chemokine receptor antagonists lead to a rapid and substantial PBSC mobilization.
The most advanced data are available for plerixafor (AMD3100), which acts synergistically with G-CSF in normal donors and patients with MM and NHL. 4 This CXCR4 antagonist seems to mobilize more primitive PBSCs with increased repopulation capacity when compared with G-CSF. 5 Plerixafor þ G-CSF-mobilized PB progenitor cells express significantly higher amounts of genes that potentially promote superior engraftment after myeloablative therapy than G-CSF-mobilized CD34 þ PB progenitor cells. 6 This report describes the first investigational use of plerixafor in Europe in an open-label, single-arm study conducted at three sites in Germany. The addition of plerixafor (0.24 mg/kg) to a standard G-CSF mobilization regimen was evaluated for safety and efficacy when used for the collection of PBSCs for autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). This is the first study that used a quantitative DNA amplification method to identify the frequency of MM tumor cells in the PB of patients with MM after mobilization with G-CSF alone and again after the addition of plerixafor treatment. This is the first report to show that the addition of plerixafor does not seem to cause MM tumor cell contamination of the apheresis product.
Patients and methods

Study design and patient population
This was an open-label, single-arm study conducted at three sites in Germany. The study was conducted according to a protocol approved by all local ethics committees. All patients or patients' designees signed an informed consent. The data were analyzed by the study-sponsored statistician and all investigators had access to the clinical trial data. This study is registered on clinicaltrials.gov, registration number NCT00322842.
Principal inclusion criteria were: male and female patients from 18 to 70 years of age, with a diagnosis of NHL or MM and eligible for autologous transplantation; no more than three prior regimens of chemotherapy (rituximab was not considered chemotherapy); X4 weeks since the last cycle of chemotherapy; Eastern Cooperative Oncology Group performance status of 0 or 1; recovery from all acute toxic effects of prior chemotherapy; negative for HIV; and adequate hematologic, hepatic, renal and cardiac function parameters at screening. Principal exclusion criteria were: any comorbid condition which, in the view of the investigator, rendered the patient at high risk from treatment complications; failed previous stem cell collections; residual acute medical condition resulting from prior chemotherapy; brain metastases or carcinomatous meningitis; an acute infection; actual body weight exceeding 150% of ideal body weight; history of ventricular arrhythmias; and a history of paresthesias (Grade 2). In addition, patients who had deterioration of their clinical status or laboratory parameters between the time of enrollment and transplant (such that they no longer met entry criteria) might be removed from the study at the discretion of the investigators.
PBSC mobilization and transplantation
Patients initially received a mobilizing regimen of G-CSF (10 mg/kg subcutaneously) each morning for 4 days (Days 1-4), as per the standard of care. Starting the evening of Day 4, patients received plerixafor 0.24 mg/kg subcutaneously. Apheresis was initiated in the morning, 10-11 h after the evening dose of plerixafor. This regimen of G-CSF treatment each morning before apheresis and plerixafor treatment in the evening was repeated for up to 5 consecutive days.
On each day of apheresis, the number of CD34 þ cells/ mL in the apheresis product was measured by flow cytometry by local and central (Esoterix) laboratories. The target cumulative yield of CD34 þ cells/kg was X5 Â 10 6 and the minimum number of cells required for transplant was X2 Â 10 6 CD34 þ cells/kg. The number of days required to collect the minimum and target numbers of cells (up to 5 days) was recorded. The cell dose for transplantation was calculated on the basis of the patient's actual body weight. After stem cell collection and before transplantation, patients underwent myeloablative chemotherapy.
Efficacy was evaluated by the PB CD34 þ cell count (cells/ml), apheresis yield (CD34 þ cells/kg), number of days to PMN and PLT engraftment, and graft durability at 3, 6 and 12 months post transplantation. Safety was evaluated by the incidence of adverse events (AEs), serious adverse events (SAEs), clinical laboratory tests (chemistry, hematology including complete blood count with differential, urinalysis and coagulation), vital sign parameters and physical examination findings. AEs were recorded in three consecutive periods.
Period 1 encompassed the period from G-CSF mobilization (Days 1-4), G-CSF plus plerixafor mobilization (Day 5 and up to Day 10), apheresis and rest before ablative treatment. Period 2 encompassed the period from transplantation to engraftment and Period 3 encompassed the period from engraftment to 12 months post transplant. In addition, tumor cell mobilization was evaluated in patients with MM.
Assessment of tumor cell mobilization
Tumor cell mobilization was evaluated from samples obtained from a sub-population of seven patients with MM, all from the Heidelberg center. Bone marrow puncture was performed at screening (before treatment with either G-CSF or plerixafor) to obtain the primer sequence for the polymerase chain-reaction (PCR) assay. In two additional patients, it was not possible to generate allele-specific oligonucleotide (ASO) primers from the bone marrow biopsies. PB samples were obtained at three time points: screening (before G-CSF and plerixafor treatment), pre-plerixafor (after G-CSF treatment and before the first plerixafor dose) and pre-apheresis (after G-CSF plus plerixafor treatment).
The mobilization of tumor cells was evaluated by PCR as described earlier. 7 Briefly, a fragment of three complementarity-determining regions (CDRs) was amplified by PCR from DNA extracted from bone marrow biopsy samples for each patient. The amplified CDR fragments were sequenced to ensure that the correct DNA fragment was amplified. In patients with MM, bone marrow samples contain a high proportion of malignant plasma cell clones; hence, the most frequently obtained sequence is the tumor sequence. For each patient, ASO primers were designed for the CDR2 region (forward) and the CDR3 region (reverse). These primers were used in a quantitative PCR to determine a count of the number of copies of DNA conforming to the ASO primers present in PB samples taken at three time points. The count of specific ASO PCR products obtained was used to determine the frequency of tumor genes with respect to the total DNA content. The MAXLIKE computer program (a gift of F. Cremer, Universita¨t Heidelberg, Heidelberg, Germany) was used to estimate the frequency of tumor cells, expressed as a share of total peripheral blood mononuclear cells (PBMCs). 7 
Results
A total of 35 patients (31 MM and 4 NHL) are described in this report. All 35 patients received plerixafor and were analyzed for safety and efficacy. Follow-up data recording graft durability to 12 months post transplant were available for 31 patients (29 MM and 2 NHL).
Patient demographics
Patient demographics are shown in Table 1 . The majority of patients were male (20 of 35) and Caucasian (34 of 35). The median age was 58.5 years in the NHL group and 61.0 years in the MM group. All patients had received prior cytoreductive chemotherapy (mean number of cycles: 7.6) and 10 patients had received prior radiotherapy: 1 (25.0%) in the NHL group and 9 (29.0%) in the MM group. Six patients with MM had prior melphalan treatment.
Mobilization and apheresis yields
As determined by the local laboratories, in the overall patient population, the median absolute PB CD34 þ cell count increased from 21.7 cells/ml at the time just before plerixafor administration to 69.2 cells/ml at the time just before first apheresis or 10-11 h after the first dose of plerixafor. In NHL patients, PB CD34 þ cells increased from 17.8 to 64.3 cells/ml, and in MM patients, PB CD34 þ cells increased from 26.5 to 71.0 cells/ml. Treatment with G-CSF plus plerixafor resulted in a median 2.6-fold increase in PB CD34 þ cell count from the time just before plerixafor administration to the time just before first apheresis, at approximately 10-11 h after the first plerixafor dose. The median fold increase in PB CD34 þ cell counts were the same for patients with NHL (2.6-fold) and MM (2.6-fold). There were patients with PB CD34 þ cell counts o20 cells/ml before plerixafor, the lowest being 2.6 cells/ml. Despite the low PB CD34 þ cell counts before plerixafor administration, all patients were successfully mobilized.
As determined by the local laboratories, the median number of CD34 þ cells collected was 6.8 Â 
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Transplant, engraftment and graft durability Thirty-three patients underwent transplantation; one patient refused transplantation and another withdrew from the study before transplantation. In the MM group, 15 patients underwent tandem transplants. Of a total of 48 transplants performed, 5 used 45 Â 10 6 CD34 þ cells/kg, whereas the remaining used 42 Â 10 6 CD34 þ cells/kg. None of the patients received G-CSF post transplantation.
Engraftment of PMNs post transplant (second transplant in the case of tandem transplants) was assessed for 25 of 33 patients; data were missing in eight patients. The overall median number of days to PMN engraftment was 14.0 (19 days in patients with NHL and 14.0 days in patients with MM). Platelet engraftment was assessed in all 33 patients. The overall median number of days to PLT engraftment was 11.0 (17 days in patients with NHL and 11.0 in patients with MM).
Graft durability up to 12 months post transplant was assessed for 31 of 33 patients. Of the two transplanted patients who were not assessed for graft durability, one died of disease progression and the other did not complete the 12-month follow-up visit. There were no reports of graft failure during the study.
Safety assessment
Overall, 24 of 35 (68.6%) patients experienced at least 1 AE (NHL 4 of 4 and MM 20 of 31). The most common AEs were anemia, thrombocytopenia, diarrhea, nausea, vomiting, herpes zoster, pneumonia, headache, hypokalemia and paresthesia. Two (5.7%) patients experienced AEs of severe intensity (not drug related) and 2 (5.7%) patients in the MM group experienced AEs considered life threatening (pneumonia requiring oxygen and sepsis) but not drug related.
One patient with NHL died during the study period. The death was due to disease progression, not considered related to plerixafor, and occurred during the post transplant follow-up period.
A total of 15 SAEs were reported for 8 patients, none of which were drug related. The majority of the SAEs reported occurred in Period 3. Only 1 SAE (type II diabetes mellitus) occurred during Period 1.
Tumor cell mobilization Apheresis yields and relative tumor cell contamination from PB samples taken at three time points (screening, before plerixafor, after plerixafor) for the seven patients with MM are shown in ) CD34 þ cells/kg were collected from these 7 patients. One patient did not have tumor cells assessed from PB screening. The frequency of tumor cells per total PBMCs at screening was compared with the frequency at the preplerixafor time point to quantify tumor cell mobilization after mobilization with G-CSF alone. It was determined that with G-CSF alone, the frequency of tumor cells increased for 5 of 6 patients and the increase ranged from 2.86-to 4.36-fold. One patient showed a 0.67-fold decrease. 
Discussion
The results of the study indicated that the PB CD34 þ count increased from pre-to post-plerixafor treatment by an overall median of 2.6-fold. This was consistent with previous reports of mobilization with plerixafor plus G-CSF where a median increase of 2.6-fold increase in PB CD34 þ cells was observed. 8 The generally accepted minimum number of cells for transplantation is X2 Â 10 6 CD34 þ cells/kg, and the preferred number of cells for transplantation is generally X5 Â 10 6 CD34 þ cells/kg. 9 The median number of CD34 þ cells collected in this study after mobilization with plerixafor plus G-CSF was 6.8 Â 10 6 cells/kg and all patients reached the minimum target CD34 þ cell collection of X2 Â 10 6 cells/kg. The majority of patients (32 of 35, 91.4%) met the target CD34 þ cell collection of X5 Â 10 6 cells/kg. The number of days from transplant to PMN engraftment is relatively consistent for patients with MM and NHL. Engraftment of PMNs usually occurs by 12 days post transplant, but may be as late as 21 days. 10, 11 The success rate of engraftment after autologous PBSC transplant was reported to be 490%.
11 Thirty-three of the 35 patients who were treated with plerixafor plus G-CSF in this study underwent transplants and 15 patients with MM received tandem transplants. The time to PMN engraftment (median 14.0, maximum 74.0 days) and time to PLT engraftment (median 11.0 days, maximum 25.0 days) was consistent with that reported from the literature. It is important to note that in this study G-CSF was not administered post transplant and PMN engraftment was observed later than in previous trials of plerixafor where G-CSF was administered post transplant.
12 G-CSF treatment has been shown to promote earlier engraftment of PMNs after autologous PBSC transplant. 13, 14 All patients assessed in this study had durable grafts at 12 months.
There were no unexpected safety findings in this study and plerixafor seemed to be well tolerated. The spectrum of AEs observed in this study was similar to that observed previously where diarrhea, injection site erythema, and nausea/vomiting were the AEs most commonly associated with plerixafor. 8, 15 AEs including bone pain, fatigue, headache and nausea/ vomiting were consistent with the expected effects of plerixafor treatment, G-CSF treatment and apheresis.
Tumor cells can be detected in the PB of patients with cancer and can contaminate stem cell products collected by apheresis or bone marrow harvest. [16] [17] [18] Standard cancer treatments such as chemotherapy and radiation can induce significant mobilization of tumor cells and lead to increased metastases. 19 Similarly, common methods used to mobilize stem cells such as chemotherapy and cytokines can also mobilize tumor cells and lead to significant contamination of stem cell products. [19] [20] [21] We thus assessed the potential tumor cell mobilization effect of plerixafor by measuring the frequency of tumor cells compared with the total PMBCs. If plerixafor caused tumor cells to mobilize, the frequency of tumor cells per the total PBMCs would be expected to increase between the pre-plerixafor and pre-apheresis (post-plerixafor) time points. After treatment with plerixafor, the relative number of tumor cells per total PBMCs either decreased or increased only slightly (not clinically or statistically significant) over that seen with G-CSF alone. Therefore, consistent with previous reports, G-CSF can induce a small amount of tumor cell mobilization. However, the addition of plerixafor did not increase the percentage of tumor cells per total PBMCs, which indicates that plerixafor does not contribute significantly to the mobilization of MM tumor cells as measured in this study.
Interestingly, the clinical effect of tumor cell contamination of the stem cell product and subsequent reinfusion of tumor cells into the recipient remain controversial. Though some studies have shown that tumor cell contamination may affect clinical outcome, 22 many other studies have shown the opposite result with no effect on progression-free survival or overall survival. 19, [23] [24] [25] [26] In some studies, the impact of contamination reached statistical significance only when the quantity of tumor in the stem cell product was very high. 21 Most of these studies were performed in an uncontrolled or retrospective manner. Importantly, in two large, prospective, randomized controlled trials of tumor cell purging, despite large differences in the level of tumor cell contamination of the stem cell product, no effect on clinical outcome was observed. 25, 26 Collectively, the data presented in this manuscript and those from previous studies of plerixafor [27] [28] [29] [30] [31] suggest that the frontline use of plerixafor enhances CD34 þ stem cell mobilization, regardless of whether the patient was a 'good' or 'poor' mobilizer. Plerixafor increases the number of patients achieving both minimum and maximum CD34 þ cells/kg and does so in fewer apheresis sessions, allows for increased predictability of apheresis yield and timing, and enables more patients to proceed to transplant with prompt and durable engraftment.
In conclusion, the first study of plerixafor conducted in Europe for mobilization of PB CD34 þ cells showed a similar efficacy and safety profile to previous clinical trials. Most importantly, this is the first study that showed that plerixafor did not increase tumor cell mobilization as measured by PCR in patients with MM.
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